JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zenke, F. T.
Right arrow Articles by Bokoch, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zenke, F. T.
Right arrow Articles by Bokoch, G. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 46, 32565-32573, November 12, 1999


Identification of a Central Phosphorylation Site in p21-activated Kinase Regulating Autoinhibition and Kinase Activity*

Frank T. ZenkeDagger , Charles C. King§, Benjamin P. Bohl, and Gary M. Bokoch

From the Departments of Immunology and Cell Biology, The Scripps Research Institute, La Jolla, California 92037

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

p21-activated kinases (Pak)/Ste20 kinases are regulated in vitro and in vivo by the small GTP-binding proteins Rac and Cdc42 and lipids, such as sphingosine, which stimulate autophosphorylation and phosphorylation of exogenous substrates. The mechanism of Pak activation by these agents remains unclear. We investigated Pak kinase activation in more detail to gain insight into the interplay between the GTPase/sphingosine binding, an intramolecular inhibitory interaction, and autophosphorylation. We present biochemical evidence that an autoinhibitory domain (ID) contained within amino acid residues 67-150 of Pak1 interacts with the carboxyl-terminal kinase domain and that this interaction is regulated in a GTPase-dependent fashion. Cdc42- and sphingosine-stimulated Pak1 activity can be inhibited in trans by recombinant ID peptide, indicating similarities in their mode of activation. However, Pak1, which was autophosphorylated in response to either GTPase or sphingosine, is highly active and is insensitive to inhibition by the ID peptide. We identified phospho-acceptor site threonine 423 in the kinase activation loop as a critical determinant for the sensitivity to autoinhibition and enzymatic activity. Phosphorylation studies suggested that the stimulatory effect of both GTPase and sphingosine results in exposure of the activation loop, making it accessible for intermolecular phosphorylation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Localized regulation of protein kinase activity is an essential means to ensure spatial and temporal control of signaling events in a cellular environment. Hormonal or other stimuli are usually necessary to switch a kinase into a catalytically competent state, allowing phosphorylation of substrates to take place. An emerging regulatory theme is that inhibitory mechanisms exist to keep protein kinases in an inactive state (1, 2), and that relief of such inhibition allows activation to occur. Kinases often act autocatalytically to phosphorylate key amino acid residues that relieve autoinhibition and enhance catalytic efficiency. Alternatively, exogenous kinases may also serve this role. However, activation must be reversed in the absence of the stimulus, and dephosphorylation by protein phosphatases is thought to mediate switching the active kinase back to an inactive or basally activated state.

p21-activated kinases (Paks)1 belong to a growing family of serine/threonine kinases involved in the control of various cellular processes, including the cell cycle, dynamics of the cytoskeleton, apoptosis, and transcription (3). Pak kinase activity is regulated by members of the Rho family of GTPases, specifically Cdc42 and Rac. These GTPases bind to Pak kinase solely in their active forms, i.e. the GTP-bound state, resulting in stimulation of the kinase activity both in vitro and in vivo. The molecular details of how the GTPases exert their effect on the kinase to induce its activation remain unclear, however. Several lines of evidence suggested that the amino-terminal non-kinase region of Pak, in which the Cdc42/Rac-binding site is located, is crucial for the regulation of kinase activity. It has been shown by several groups that removal of the NH2-terminal portion of Pak by protease digestion leads to activation of the kinase fragment (4, 5). A physiologically relevant example is known for the 62-kDa isoform Pak2, which has been shown to be cleaved and activated by the cysteine protease caspase-3 in response to apoptosis-inducing stimuli (6-8).

Zhao et al. (9) have recently used mutational analysis to characterize a region in the NH2-terminal regulatory domain of Pak adjacent to the p21-binding domain that is important for the inhibition of kinase activity. Using a plasmid injection approach, they showed that cellular effects that depend on Pak kinase activity, including dissolution of actin stress fibers and focal adhesions, can be blocked by coexpression of the autoinhibitory region. Similar conclusions were reached using a genetic analysis of Schizosaccharomyces pombe Pak1 (10). We undertook a biochemical approach to characterize an interaction between the Pak1 kinase domain and the regulatory amino terminus. We localized the interacting site in the NH2 terminus to the same area as the autoinhibitory domain (ID) characterized by Zhao et al. (9). Our data suggest that the interaction observed is responsible for maintaining the kinase in an inactive state. Cdc42 was able to disrupt the interaction, but only in the GTP-bound active form. Using characterized mutations in Pak1 that abolish GTPase binding or inactivate the inhibitory function, we could show that the p21-binding and autoinhibitory domains are separable but overlapping. Recently, we have demonstrated that sphingosine is an activator of human Pak1 in vitro and in vivo (11), although the activation by the lipid in vivo is controversial (12). We observed that, at non-saturating concentrations, sphingosine-induced Pak1 activation was also sensitive to the autoinhibitory peptide, suggesting that the lipid mediates activation of Pak1 via a similar mechanism, i.e. relief of autoinhibition by the NH2-terminal ID domain. We demonstrate that one major phosphorylation event on residue threonine 423 within the COOH-terminal kinase domain renders the kinase activity independent of the autoinhibitory module and simultaneously increases its specific activity. Both Cdc42 and sphingosine act on Pak1 kinase to expose threonine 423, which in turn becomes accessible for cross-phosphorylation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Cell culture medium, fetal bovine serum and supplements were from Life Technologies, Inc. [gamma -32P]ATP (specific activity 4500 mCi/mmol) was from ICN, Costa Mesa CA. Plasmids for transfection were purified using the Qiafilter purification system of Qiagen, Chatsworth CA. The T7-tag monoclonal antibody was purchased from Novagen, Madison WI. Thrombin and sphingosine were purchased from Sigma; GTPgamma S and [35S]GTPgamma S were from NEN Life Science Products. For polymerase chain reactions, the Expand High Fidelity PCR system from Roche Molecular Biochemicals was used. The PKCbeta II antibody (originally raised against a subdomain VIII phosphopeptide of the protein kinase C isoform beta II, kindly provided by Erica Dutil and Alexandra Newton, University of California, San Diego, CA) was used to detect the threonine 423 phosphorylated subdomain VIII activation loop of Pak1.

Plasmid DNA and Constructions-- pGEX-KG/rpak1 (233-544) was kindly provided by Melanie H. Cobb (University of Texas Southwestern Medical Center, Dallas, TX). pCMV6M is a myc tag-containing derivative of pCMV5 and has been described elsewhere (13). All Pak1 variants (human Pak1 wild type, Pak1-(T423E), Pak1-(T423A), Pak1-(H83L,H86L), Pak1-(L107F), Pak1-(K299A) were inserted into pCMV6M and contain a myc epitope at the amino terminus for detection. The threonine to alanine exchange at position 423 in hPak1 was introduced using oligonucleotides (5'-CAGAGCAAACGGAGCgCCATGGTAGGAACCCC-3' and the complementary oligonucleotide) and the Quikchange Site-directed mutagenesis kit of Stratagene, La Jolla.

The NH2-terminal fragments of hpak1 (amino acid 1-234: hpak1-(1-234), aa 67-150: hpak1-(67-150) and mutated derivative H83L,H86L) were subcloned in pET28a (Novagen, Madison). The wild type and H83L,H86L mutation of hpak1-(1-234) were amplified by PCR from the corresponding pCMV6M/hPak1 derivatives using primers pT637 and OP1/234-3' (5'-CCG GAA TTC TTA AGC ATC TGG TGG AGT GGT-3'), cut with BamHI and EcoRI, and inserted into BamHI-EcoRI-cut pET28a. The p21-binding domain (PBD)/ID wild type fragment (amino acid 67-150) was produced by PCR using primers OP1/67-5' (5'-CGC GGA TCC AAG AAA GAG AAA GAG CGG-3') and OP1/150-3' (AAG GAA AAA AGC GGC CGC GTC GAC TCA AGC TGA CTT ATC TGT AAA GCT-3'), cut with BamHI and EcoRI, and inserted into pET28a. The PBD/ID fragments containing the H83L,H86L or the L107F mutations were amplified from the corresponding full-length hPak1 cDNA clones and inserted by BamHI and EcoRI restriction into pET28a. To produce H83L and H86L single mutations in the PBD/ID fragment, overlapping PCR was performed using OP1/67-5' and OP1/150-3' as outer boundary primers and overlapping primer pairs to introduce the desired mutations (for H83L: forward primer 5'-TCA GAT TTT GAg CtC ACA ATT CAT-3' and reverse primer 5'-ATG AAT TGT GaG cTC AAA ATC TGA-3'; for H86L: forward primer 5'-GAA CAC ACA Ata Cta GTC GGT TTT-3' and reverse primer 5'-AAA ACC GAC taG tAT TGT GTG TTC-3'; lowercase letters indicate the introduced base mutations).

The COOH-terminal kinase domains of human Pak1 (amino acids 232-545) was amplified by PCR (primers for hpak1-(232-545): 5'-GC GGA TCC CCA GAT GCT TTG ACC CGG-3', 5'-G CCG GTC GAC TTA GTG ATT GTT CTT TG-3'). The hpak1 fragment was cut with BamHI-SalI and inserted into BamHI-SalI-cut pET28a.

Purification of Recombinant Proteins-- The GST-rpak1-(233-544) protein was expressed in DH10B cells and purified according to the standard protocol of Amersham Pharmacia Biotech, Uppsala, Sweden (GST gene fusion system, 3rd edition). Buffers for GST-Cdc42 purification contained 1 µM GDP starting from the lysis, excluding the dialysis buffer. The GST moiety was cleaved off the Cdc42 with thrombin at a final concentration of 10 units/ml glutathione beads. Thrombin was removed by incubation with p-aminobenzamidine beads (Sigma) and Cdc42 dialyzed four times against buffer (25 mM Tris/HCl, pH 7.5, 1 mM EDTA, 5 mM MgCl2, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride). After dialysis, 1 µM GDP was added again and the purified protein was concentrated by ultrafiltration.

His-tagged fusion proteins in vector pET28a were expressed in BL21/DE3 (pLysS). The recombinant kinase fragment (hpak1-(232-545)) was purified following the standard batch purification protocol under native conditions (Qiagen QIAexpressionist, March 1997). The histidine-tagged fusion proteins, hpak1-(1-234) and hpak1-(67-150), were purified under denaturing conditions according to the batch purification method by Qiagen. After elution the proteins were dialyzed twice against 2 liters of buffer (50 mM Hepes/NaOH, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 5% glycerol) and stored frozen at -70 °C.

Binding Assay-- Rat Pak1 kinase fragment (amino acids 233-544) fused to glutathione S-transferase (GST-rpak1-(233-544)) and an NH2-terminal His6/T7-tagged fusion of human Pak1 hpak1-(1-235) were purified and used for in vitro binding studies. The rat Pak1 COOH-terminal kinase domain does not differ in amino acid sequence from the human homologue (sequencing of human Pak1 revealed that amino acid 503 in human Pak1 is glutamic acid, codon GAG, and not aspartic acid, codon GAT, as in the GenBank data base sequence). 1-5 µg of GST-rpak1-(233-544) kinase domain was incubated with 1-3 µg of NH2-terminal protein fragments in binding buffer (50 mM Hepes/NaOH, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT, 1% Nonidet P-40) in a volume of 200-500 µl. To immobilize the GST protein, glutathione-agarose beads equilibrated in binding buffer were added to the reaction and incubated for 30 min to 1 h at 4 °C under constant agitation. Binding reactions were washed four times with 1 ml of binding buffer each. Samples were boiled in SDS-sample buffer and separated on SDS-PAGE gels for immunoblotting or Coomassie staining.

In Cdc42 competition experiments, the binding reactions were washed twice with binding buffer to remove unbound hpak1-(1-234) and Cdc42 was added to the complex for 15 min on ice or for 15 min at 30 °C as indicated in the figure legends. The bead fraction was washed again four times with binding buffer and prepared for SDS-PAGE.

Transfections and Immunoprecipitations-- Cos-1 or HeLa cells were seeded on 10 cm cell culture dishes at 50-70% confluency and transfected using LipofectAMINE (Life Technologies, Inc.) as a transfection agent. 5 µg of plasmid DNA and 15 µl of LipofectAMINE were used per dish, and the transfection protocol was essentially followed according to the manufacturer's guidelines (Life Technologies, Inc.). After 48 h the dishes were washed once with 1× Hanks' buffered saline solution (Life Technologies, Inc.) and lysed in 0.5 ml of lysis buffer (25 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 10% glycerol, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride). The expression of proteins in the lysates was analyzed by immunoblotting. For precipitations of myc-tagged hPak1, lysates were incubated with equilibrated protein G beads and monoclonal anti-myc antibody (9E10) for at least 3 h or overnight at 4 °C. The bead fraction was washed four times with lysis buffer, stored frozen at -70 °C, or directly used for kinase assays. To use immunoprecipitated hPak1 in kinase assays, the bead fraction was washed twice in kinase buffer.

Loading of Cdc42 and Preparation of Sphingosine-- Cdc42 was loaded with GTPgamma S under the following conditions. 5-20 µg of Cdc42 were incubated in 25 mM Hepes/NaOH, pH 7.5, containing 20 mM EDTA and 1 mM GTPgamma S for 10 min at 30 °C in a total volume of 25-100 µl. The reaction was stopped by addition of MgCl2 at 100 mM final concentration.

Sphingosine was dissolved in 95% ethanol at a concentration of 15 mM and stored at -20 °C. Aliquots were dried under nitrogen gas and dissolved in 25 mM Tris/HCl, pH 7.5, at 3-4 mM concentration. Before addition of sphingosine to the kinase reaction, the lipid solution was sonicated for 30-60 s.

In Vitro Kinase Assays-- Kinase reactions with purified recombinant or immunoprecipitated Pak were performed in kinase buffer (50 mM Hepes/NaOH, pH 7.5, 10 mM MgCl2, 2 mM MnCl2, 0.2 mM DTT) in a volume of 60 µl with 250 µM ATP except for the experiment shown in Fig. 1D, where 50 µM ATP was used. Radiolabeled ATP was used at 10 µCi/reaction. The reactions were incubated for 30 min at 30 °C and stopped by addition of sample buffer. Myelin basic protein (MBP) was used as a substrate at 2-4 µg/reaction.

To prephosphorylate Pak prior to a kinase reaction, the protein G-bound hPak1 was incubated with 250 µM unlabeled ATP and an activator (0.5-2 µg of GTPgamma S-loaded Cdc42 or 0.4 mM sphingosine) for 30 min at 30 °C. The reactions were washed three times with lysis buffer and twice with kinase buffer and directly used in kinase assays as described above.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interaction between the Pak1 Kinase Domain and a NH2-terminal Region-- Pak kinases consist of a NH2-terminal regulatory domain and a COOH-terminal kinase domain having many of the conserved features of all known serine/threonine kinases. Several lines of evidence have suggested that the NH2-terminal region down-regulates the enzymatic activity of the COOH-terminal kinase. We tested whether we could detect a physical interaction between these domains that might be responsible for inhibiting Pak kinase activity.

As seen in Fig. 1A, the purified hpak1-(1-234) fragment efficiently complexed with the bead-coupled GST-rpak1-(233-544) COOH-terminal piece containing the entire kinase domain. Binding was specific to the GST-rpak1-(233-544) fusion since the amino terminus was not precipitated with GST alone. Incubating the preformed GST-rpak1-(233-544)/NH2 terminus complex with GTPgamma S-loaded Cdc42 reduced the amount of the hpak1-(1-234) in the pull-down fraction (Fig. 1A, lane 4). This reduction was specific for GTPgamma S-loaded Cdc42, as a GDP-loaded or a non-loaded Cdc42 was not able to compete (Fig. 1B). Addition of GTPgamma S-loaded Cdc42 decreased complex formation in a concentration-dependent manner (Fig. 1C). A hpak1-(1-234) fragment in which the Cdc42-binding site was mutated (H83L,H86L) bound as efficiently as the wild type fragment to the kinase domain (Fig. 1C, compare lanes 2 and 7). However, in this case the GTPgamma S-loaded Cdc42 was not able to disrupt the interaction, indicating that binding of the GTPase to the NH2-terminal fragment is required for the observed competitive effect. In vitro kinase assays showed hpak1-(1-234) is capable to inhibit GST-rpak1-(233-544) kinase activity (Fig. 1D, lanes 3-6). With increasing amounts of the NH2 terminus, autophosphorylation and phosphorylation of myelin basic protein were decreased. However, hpak1-(1-234) itself was a good substrate for GST-rpak1-(233-544) (data not shown) and this, due to competitive substrate phosphorylation, made it difficult to determine the Ki value.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Interaction between the amino-terminal hpak1-(1-234) fragment and the carboxyl-terminal Pak1 kinase domain and inhibition of kinase activity. A, 10 µg of glutathione S-transferase (GST) or the GST-rpak1-(233-544) fusion protein coupled to glutathione-agarose beads was incubated with 10 µg of the NH2-terminal His/T7-tagged hpak1-(1-234) in 150 µl of binding buffer for 15 min at 4 °C. The bead fraction was washed twice in binding buffer and then incubated with 10 µg of GTPgamma S-loaded Cdc42 (lanes 2 and 4) on ice. Binding reactions were washed again, and half of the reaction was electrophoresed on a 10% SDS-polyacrylamide gel. The Coomassie-stained gel is shown. B, 5 µg of GST or GST-rpak1-(233-544) bound to glutathione-agarose beads was incubated with 7.5 µg of hpak1-(1-234) in 130 µl of binding buffer as described under A. 5 µg of GTPgamma S- or GDP-loaded or unloaded Cdc42 was incubated with the bead-bound fraction, the beads were washed, and proteins separated by SDS-PAGE. The NH2 terminus was immunodetected with the T7 tag antibody. C, binding conditions as in B. The indicated amounts of GTPgamma S-loaded Cdc42 were incubated with the bead-bound proteins for 15 min at 30 °C. The washed bead-bound fraction was separated by SDS-PAGE and immunodetected with the T7 tag antibody. Note that two hpak1-(1-234) bands are detected in C due to residual thrombin activity in the Cdc42 preparation. D, hpak1-(1-234) inhibits GST-rpak1-(233-544) kinase activity. A constant amount of GST-rpak1-(233-544) (1 µg) was preincubated with the indicated amounts of hpak-(1-234), dialysis buffer (lane 7), or 6 µg of bovine serum albumin (lane 8), and a kinase reaction was performed. Adenosine triphosphate was used at 50 µM concentration, myelin basic protein at 2 µg/reaction. An autoradiograph of the electrophoresed kinase reactions is shown. Note that, on this and subsequent figures, fragment numbers are given as superscripts.

Cdc42 binds Pak1 in a minimal region consisting of amino acids 75-89 (14). However, amino acids surrounding this sequence contribute to the efficiency of the interaction (9). We hypothesized, based on the Cdc42 competition experiments (Fig. 1), that the domain interacting with the kinase core might be in close vicinity or overlap with the Cdc42 binding site. To localize the carboxyl-terminal interacting and autoinhibitory domain in the NH2 terminus, we expressed smaller regions of human Pak1 as recombinant His6/T7-tagged proteins in Escherichia coli and tested these in pull-down assays with GST-rpak1-(233-544) immobilized on glutathione-agarose. We detected a very efficient interaction with a His6/T7-tagged fusion of the wild type hpak1-(67-150) peptide (Fig. 2A, lane 4). The amino-terminal fragment did not bind to the GST protein (Fig. 2A, lane 3), demonstrating the specificity of this interaction. Other amino-terminal Pak fragments (amino acids 1-74 and 174-306) were not pulled down by the COOH-terminal fragment (data not shown). The region encompassing amino acids 67-150 contains the previously characterized GTPase/p21-binding domain and confirmed our hypothesis that the interaction site is in close proximity to the p21 binding domain. To further refine the interacting region, we constructed smaller peptides of hPak1 (aa 67-89, 67-108, and 109-150). However, we could not detect an interaction of these peptides with the Pak1 kinase domain using the pull-down assay (data not shown).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   Interaction of the GST-rpak1-(233-544) kinase domain with hpak1-(67-150) and inhibition of kinase activity. A, upper panel, the His6/T7-tagged amino-terminal fragments hpak1-(67-150) (wild type (wt) and mutants indicated by amino acid change introduced and its position) were purified by denaturing chromatography on Ni-NTA. As a control, an eluate from control vector (pET28a) expressing E. coli was purified and used in binding experiments and kinase reactions (lane 1). Shown are the electrophoresed peptides (normalized for protein) used in the binding assay below. Lower panel, 5 µg of GST or 2.5 µg of GST-rpak1-(233-544) was incubated with 1.2 µg of the indicated hpak1-(67-150) proteins and glutathione-agarose beads for 1 h at 4 °C and washed four times with binding buffer. Binding reactions were resolved on a 13% SDS-polyacrylamide gel. The Ponceau S-stained GST and GST-rpak1-(233-544) are shown in the upper panels. The hpak1-(67-150) and mutated fragments recovered in the bead fraction were detected with the T7 tag antibody. B, a kinase assay was performed using GST-rpak1-(233-544) (0.5 µg/reaction) in the presence of the indicated hpak1-(67-150) peptides. The purified peptides were used at 1 and 2 µM concentration, respectively, in the kinase assay. The phosphorylated GST-rpak1-(233-544) and MBP are labeled on the autoradiograph.

We employed already characterized mutations within hpak1-(67-150) to further analyze the function of this region. Mutation of both conserved histidine residues to leucine (H83L,H86L) has been shown to disrupt the interaction with small GTPases, accompanied by a moderate increase in kinase activity (13, 15). Mutating leucine 107 to phenylalanine, on the other hand, leads to strong activation of full-length Pak1, and activity is independent of GTPases (16), even though binding is maintained. We analyzed how these mutations influence the interaction with the GST-rpak1-(233-544) fusion. As seen in Fig. 2A (lanes 5-12), the H83L and H86L single and double mutants bound as efficiently to the kinase domain as did the wild type peptide. In contrast, the L107F mutation exhibited drastically reduced binding to the kinase domain.

The purified hpak1-(67-150) fragments had different abilities to inhibit GST-rpak1-(233-544) kinase (Fig. 2B). The wild type hpak1-(67-150) was most potent in inhibiting kinase activity, whereas the L107F mutated peptide was strongly reduced in its inhibitory potency, and the H83L,H86L double mutant was moderately reduced in inhibiting GST-rpak1-(233-544) kinase activity. The hpak1-(67-150) fragments, unlike hpak1-(1-234), were not phosphorylated substantially. We termed the hpak1-(67-150) region PBD/ID (p21 binding domain/inhibitory domain).

Influence of hpak1-(67-150) Peptides on Cdc42-stimulated hPak1 Kinase Activity-- Using GST- rpak1-(233-544) kinase to evaluate the inhibitory potential of the PBD/ID region (aa 67-150) had the advantage that the isolated COOH terminus is constitutively active, independently of GTPases. However, we asked whether Cdc42-stimulated hPak1 activity could also be inhibited by the purified peptides. Since a functional p21 binding site is contained within the PBD/ID fragment, it was expected that inhibition of kinase activity could in part be due to sequestering of the GTPases. The ability of the PBD/ID fragments to bind activated Cdc42 was tested (Fig. 3). Only the wild type fragment and the L107F mutated form could bind Cdc42 in overlay assays, although the latter bound with somewhat reduced affinity (about 50% of wild type). Mutation of histidines 83 and 86 either separately or together led to a complete loss of binding to Cdc42. Any kinase inhibition by these Cdc42 binding-deficient fragments would therefore not be due to titration of GTPases.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Binding of activated Cdc42 to hpak1-(67-150) and its mutated derivatives. The His/T7-tagged amino-terminal peptides (aa 67-150) were normalized and separated by SDS-PAGE on a 13% polyacrylamide gel. The upper panel shows the Ponceau S-stained hpak1 peptides blotted onto the membrane. The blotted proteins were subjected to a GTPase-overlay assay as has been described (20). The immobilized proteins were incubated with [35S]GTPgamma S-labeled Cdc42 and the bound GTPases were visualized by autoradiography (lower panel).

We were able to show that not only the Cdc42-binding proficient, but also the binding-deficient versions were able to inhibit full-length hPak1 activity. As Fig. 4A shows, both autophosphorylation and substrate phosphorylation are reduced by hpak1-(67-150) peptides. The wild type and L107F mutant peptides strongly reduce kinase activity. The inhibition by the L107F peptide is most likely due to sequestration of the activated Cdc42. Of the GTPase binding-deficient versions, the H83L mutant peptide was most potent in its kinase-inhibitory effect. Mutation of position 86 significantly reduced the inhibitory effect to a similar extent as did the H83L,H86L double mutant. All peptides showed concentration-dependent inhibitory effects. We titrated the H83L peptide to determine the half-maximal inhibitory concentration using a constant amount of immunoprecipitated hPak1 stimulated with Cdc42 (Fig. 4B). The purified peptides were not significantly phosphorylated and therefore did not interfere with the Ki determination. We calculated the apparent Ki as 1.2 µM for MBP phosphorylation (Fig. 4C). Overall, the peptide inhibition data obtained with p21-activated Pak1 fit well with those using GST-rpak1-(233-544) (Fig. 2C). Taken together, these data demonstrate that the functional domains for p21 binding and autoinhibition of kinase activity overlap in part within the PBD/ID. Both activities can, however, be separated from each other, demonstrating that the PBD and the ID have distinct structural determinants for function.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of Cdc42-stimulated full-length hPak1 activity by hpak1-(67-150) peptides. A, normalized concentrations of the indicated hpak1-(67-150) peptides were used for this kinase assay as shown in the Coomassie-stained gel (upper panel). Immunoprecipitated wild- type hPak1 was used at a constant amount per reaction, and the purified hpak1-(67-150) peptides were added at final concentrations of 2 and 4 µM. 1.25 µg of GTPgamma S-loaded Cdc42 was added to the reactions as indicated. Kinase reactions were performed in the presence of 250 µM ATP with 4 µg of MBP as a substrate. The middle panel shows an autoradiograph of the electrophoresed kinase reactions. Phosphorylated hPak1 and myelin basic protein are labeled. A quantification of the PhosphorImager data is presented in the lower panel. As a reference Cdc42-stimulated auto- and substrate phosphorylation (lane 2) were set to 100%. B, a constant amount of immunoprecipitated wild type hPak1 was assayed in the presence of increasing concentrations of H83L hpak1-(67-150) (0.4, 1, 2, 4, and 8 µM final; lanes 8-12) or the control eluate (lanes 3-7, see legend of Fig. 2). A constant amount of GTPgamma S-loaded Cdc42 (0.7 µg/reaction) was added to the kinase reaction as indicated. Myelin basic protein was used at 4 µg/reaction. C, graphic representation of the phosphorimaging data shown in B. Cdc42-stimulated MBP phosphorylation by wild type hPak1 (see B, lane 2) was set to 100%. The concentration to get half-maximal inhibition was calculated to 1.2 µM.

Effect of Autophosphorylation on Inhibition by the ID Domain-- Pak kinases autosphosphorylate after stimulation with activated Cdc42 and remain activated after removal of the GTPase (17). In light of our above results, this could indicate that phosphorylation events antagonize the inhibitory effect of the ID domain by decreasing its interaction with the kinase domain. Full-length hPak1 was activated by autophosphorylation for 30 min in the presence of excess unlabeled ATP and Cdc42-GTPgamma S; these were then removed by washing (Fig. 5A). As shown in lanes 3-7, in a subsequent kinase reaction with labeled ATP the incorporation of label into hPak1 was drastically decreased due to an efficient incorporation of unlabeled ATP in the initial reaction. Autophosphorylated hPak1 was highly active toward substrate even without further addition of activated Cdc42. The hpak1-(67-150) wild type peptide and also the mutated versions (data not shown) did not affect substrate phosphorylation activity of the autophosphorylated Pak1 at levels sufficient to efficiently block Cdc42-stimulated hPak1. Addition of activated GTPase to prephosphorylated hPak1 did not restore the sensitivity toward ID-mediated inhibition (data not shown). We also observed that the hPak1 kinase domain (aa 232-545), when expressed as a His6/T7-tagged fusion protein in E. coli, is autophosphorylated and also not inhibited by excess concentrations of PBD/ID peptide (data not shown), supporting the idea that phosphorylation renders the kinase domain independent of autoinhibition.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   Prephosphorylated hPak1 and hPak1-(T423E) are not inhibited by the PBD/ID peptides. Upper panel, immunoprecipitated wild type hPak1 was prephosphorylated in the presence of GTPgamma S-loaded Cdc42 (lanes 3 and 7) and used in kinase reactions in comparison to untreated hPak1 (lanes 1 and 2). The amount of immunoprecipitated hPak1 was kept constant in all reactions. 1.5 µg of Cdc42 was added to the kinase (lane 2) and prephosphorylation reactions (lanes 3-7). Control Ni-NTA eluate (buffer control, co) or wild type hpak1-(67-150) (2 and 4 µM, wt) was added to the reactions. hPak1 and MBP signals are indicated. Lower panel, a constant amount of immunoprecipitated hPak1-(T423E) was used per kinase reaction. Control Ni-NTA eluate and wild type hpak1-(67-150) peptide (2 and 4 µM) were added as indicated.

Interestingly, a hPak1 mutant, hPak1-(T423E) (13), which is constitutively activated by mutation at phospho-acceptor site threonine 423 in the activation loop, is also completely inert toward inhibition by the PBD/ID fragments (Fig. 5B). In this case, both autophosphorylation and substrate phosphorylation are not affected by the hpak1-(67-150) peptide. This argues that the phosphorylation state of threonine 423 is a critical determinant for kinase inhibition by the ID domain.

Importance of Threonine 423 for Kinase Activity and Autoinhibition-- As indicated by the threonine 423 to glutamic acid mutation in hPak1, the phosphorylation status of the activation loop appears to be of importance for the autoinhibitory mechanism. To analyze this in more detail, we constructed a threonine 423 to alanine mutant that does not autophosphorylate at this residue, and the activity of this mutant was compared with the wild type protein in in vitro kinase assays.

Basal activities of immunoprecipitated T423A hPak1 did not differ from wild type (Fig. 6, lanes 1 and 6). The Cdc42-stimulated hPak1 T423A had a decreased activity toward exogenous substrate, ranging from 10 to 30% of wild type activity (Fig. 6, compare lanes 2 and 7). Autophosphorylation was less affected and in the range of 40-60% of wild type Pak1. The Cdc42-stimulated hPak1-(T423A) activity was sensitive to inhibition by the H83L hpak1-(67-150) fragment. Prephosphorylation of hPak1-(T423A) in the presence of GTPgamma S-loaded Cdc42 and excess cold ATP led to a significant decrease in the incorporation of radioactivity into the protein in a subsequent kinase reaction. The prephosphorylated hPak1-(T423A) retained its (reduced) activity toward substrate but surprisingly this activity was still sensitive toward addition of hpak1-(67-150) fragment (Fig. 6, lane 10).


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 6.   Phenotype of the threonine 423 to alanine mutation in hPak1. Wild type hPak1 and hPak1-(T423A) were immunoprecipitated from Cos-1 lysates and protein levels were normalized prior to the kinase assay. 1.5 µg of Cdc42 loaded with GTPgamma S was added to prephosphorylation and kinase reactions as indicated. MBP was used as a substrate at 4 µg/reaction. The H83L-hpak1-(67-150) peptide was used at 6 µM concentration. The autoradiograph of the electrophoresed kinase reactions is shown in the upper panel, the PhosphorImager quantification is shown in the lower panel. Residual thrombin activity in the Cdc42 preparation resulted in cleavage of myelin basic protein (labeled with * in the autoradiograph). As reference, Cdc42-stimulated wild type hPak1 activity toward MBP was set to 100%. Note that hpak1-(67-150) was phosphorylated (lane 5).

Sphingosine-mediated Activation of hPak1 and Influence on PBD/ID-mediated Inhibition-- It was of interest to analyze if lipid-mediated activation of hPak1 is sensitive to the ID/kinase domain interaction. Sphingosine, which is one of the more effective lipids to activate hPak1 (11), was used in in vitro kinase assays in the absence and presence of the PBD/ID peptide (Fig. 7). The concentration (400 µM) used in the assay resulted in a highly activated hPak1 in which auto- and substrate phosphorylation was comparable to the Cdc42-stimulated enzyme (Fig. 7A). Under these conditions, sphingosine-mediated activation was completely insensitive to the wild type PBD/ID fragment. However, we observed that activation of hPak1 with non-saturating concentrations (50 µM) of the lipid was reduced by the wild type hpak1-(67-150) peptide (Fig. 7B). Prephosphorylation of hPak1 in the presence of sphingosine led (as shown for activation by Cdc42) to an increased activity in the absence of the primary stimulus (Fig. 7A, lane 9). Sphingosine-mediated autophosphorylation is therefore sufficient to maintain Pak1 activity. In this case, where lipid was washed out after the initial incubation, the autophosphorylated activated species could clearly be shown to be unresponsive to high concentrations of the purified PBD/ID fragment (Fig. 7A, lane 10).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 7.   Influence of sphingosine on PBD/ID-mediated inhibition. Wild type hPak1 was used at a constant amount in all kinase reactions. A, hPak1 was prephosphorylated with unlabeled ATP in the presence of 1 µg of GTPgamma S-loaded Cdc42 (lanes 4 and 5) or 400 µM sphingosine (lanes 9 and 10). The same concentration of activators was used in the kinase reactions with untreated hPak1 as indicated. The hpak1-(67-150) peptide was used at 4 µM final concentration (lanes 3, 5, 8, and 10). The autorad is presented in the upper panel; the PhosphorImager quantification is shown below. Note, that due to traces of thrombin-activity in the Cdc42 preparation, a fraction of MBP was cleaved into two smaller fragments in lane 2 (labeled with *). Phosphate incorporation into these cleaved fragments was included in the PhosphorImager quantification. Phosphorylation of MBP in lane 2 was set to 100%. B, kinase assay using wild type hPak1 stimulated with the indicated concentrations of sphingosine or 1 µg of Cdc42 in the presence and absence of 4 µM wild type hpak1-(67-150).

Activator-induced Opening of the Kinase Results in Exposure and Subsequent Phosporylation of Threonine 423-- Autophosphorylation of hPak1 by sphingosine or GTPases results in increased kinase activity that is maintained even in the absence of the primary stimulus (Fig. 7A). This raised the question whether phosphorylation of hPak1 by another active Pak1 molecule (intermolecular phosphorylation) could be sufficient for activation in the absence of stimulators (GTPase, lipids).

We used recombinant His6/T7-tagged hpak1-(232-545) kinase to phosphorylate wild type human Pak1. The hpak1-(232-545) kinase fragment phosphorylated the full-length form of hPak1 overexpressed in Cos-1 cells (Fig. 8A, middle panel). Although the recombinant kinase fragment was highly active toward substrates (MBP, full-length hPak1), we were not able to see it autophosphorylate (Fig. 8, left panel), possibly due to prior autophosphorylation in E. coli (data not shown). However, intermolecular phosphorylation of full-length hPak1 did not result in, and therefore might not be sufficient for, activation (Fig. 8A, right panel).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 8.   Intermolecular phosphorylation of hPak1. A, a kinase reaction was performed using recombinant and kinase active hpak1-(232-545) to phosphorylate full-length human Pak1 in Cos1 lysates. Left panel, kinase assay with hpak1-(232-545) in the presence and absence of MBP. Middle panel, a kinase reaction was performed using lysates from Cos-1 cells expressing control vector or wild type hPak1. The hpak1-(232-545) kinase fragment was added to the reactions as indicated. Right panel, immunoprecipitated wild type hPak1 was prephosphorylated in the presence and absence of hpak1-(232-545), washed, and subjected to a kinase assay using MBP as a substrate. The activity toward MBP of the amount of hpak1-(232-545) used for cross-phosphorylation is shown on the right. B, phosphorylation of threonine 423 by hpak1-(232-545). Immunoprecipitated wild type and kinase inactive hPak1-(K299A) were incubated with 1 µg of GTPgamma S-loaded Cdc42 and 400 µM sphingosine as indicated. hpak1-(232-545) was added to the reactions as indicated. 250 µM ATP was present in all reactions. The reactions were incubated for 30 min at 30 °C, then separated on a 12% SDS-polyacrylamide gel and blotted for immunodetection using an antiserum recognizing the threonine 423-phosphorylated activation loop of hPak1. Upper panel, the Ponceau S-stained hPak1 proteins are shown. Wild type hPak1 showed significant decrease in mobility after phosphorylation with GTPgamma S-loaded Cdc42 or sphingosine. Lower panel, immunodetection of threonine 423 phosphorylation using the alkaline phosphatase color reaction.

Further evidence suggested that the key phosphorylation site threonine 423 is protected from intermolecular phosphorylation when full-length Pak1 is in an inactive conformation. A phosphospecific antiserum specifically detecting the threonine 423 phosphorylated form of the subdomain VIII activation loop showed that threonine 423 was not phosphorylated by the recombinant hpak1-(232-545) kinase (Fig. 8B, lane 7), whereas this antiserum efficiently detects the threonine 423-phosphorylated species of wild type hPak1 stimulated with Cdc42 or sphingosine (Fig. 8B, lanes 2 and 3). In this experiment the kinase-inactive hPak1-(K299A) was used to investigate the role of activator binding on threonine 423 phosphorylation (Fig. 7C, lanes 4-9). Indeed, if GTPgamma S-loaded Cdc42 or sphingosine were added together with the recombinant pak1-(233-544) kinase to hPak1-(K299A), then threonine 423 was phosphorylated.

These data suggest that the conformational status of Pak1 determines the accessibility of threonine 423 for intermolecular phosphorylation. In the closed conformation (absence of activators), this residue is not accessible. Opening of the Pak1 structure by activators eliminates these conformational restraints and leads to exposure of threonine 423 for phosphorylation. The fact that both activators qualitatively give the same results again argues that sphingosine action on the Pak1 molecule is virtually equivalent to that of Cdc42.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mechanistic Model of Pak Activation-- The data presented here suggest the following model for the regulation of Pak kinase activity (Fig. 9A). A key feature in the control of Pak enzymatic activity is a regulated interaction between an amino-terminal inhibitory domain and the catalytic kinase domain. Cdc42 and Rac GTPases that are in the active GTP-loaded conformation bind to the amino-terminal PBD and disrupt this interaction, thereby relieving initial inhibition of the kinase. Binding of the GTPase to Pak is a reversible event, i.e. when the GTPase drops off, the inhibitory mechanism can engage again and silence the kinase as long as no autophosphorylation occurs.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 9.   Model for the regulation of p21-activated kinase. A, left upper panel, Pak kinases exist in a closed conformation in the absence of an activator (GTPase, lipid) due to an interaction between the ID and the kinase domain (KD). The conformationally closed Pak has a basal level of kinase activity. Right upper panel, binding of activators (GTPase, sphingosine) leads to a conformational change to open the Pak structure, relieving the initial inhibitory constraints. (Our data suggest that binding of the lipid occurs within the PBD/ID region, but the binding requirements have not been defined yet). However, binding of the activators disrupts the ID-kinase domain interaction due to an overlap of their binding sites. The opened and unphosphorylated Pak has increased activity toward substrate. Right lower panel, as a consequence of increased kinase activity, Pak autophosphorylates at several residues, including threonine 423, which leads to a maximal increase in the enzymatic activity. Left lower panel, even if the activator dissociates from its binding site, Pak kinase activity remains high, since phosphorylation of threonine 423 and possibly serine/threonine residues in the inhibitory domain keep the kinase in an open and highly active conformation. Dephosphorylation has to occur to switch Pak back to the closed and inactive conformation. B, opening of Pak leads to intra- and intermolecular autophosphorylation. Left panel, threonine 423 in the activation loop of the kinase domain is not accessible for intermolecular phosphorylation when the Pak substrate is in the closed conformation. Right panel, threonine 423 phosphorylation (and possibly other phosphorylation events regulating the ID) only occur if the Pak substrate molecule is in an open conformation. Threonine 423 accessibility is depicted as a change in shading in this model, which should reflect a conformational change of the kinase domain in the open conformation. As an alternative, the closed conformation could also lead to masking of threonine 423.

Phosphorylation of the kinase domain at threonine 423 in the activation loop in subdomain VIII renders the enzymatic activity insensitive to the autoinhibitory module, possibly reflecting the inability of the inhibitory module to interact with the kinase domain. At this stage, the dissociation of the GTPase from Pak is no longer sufficient to inhibit enzymatic activity; instead, dephosphorylation has to occur to enable Pak to refold and engage the inhibitory module.

However, our data indicate that phosphorylation of threonine 423 serves a dual purpose, as it is also required to achieve full kinase activity. This appears to be similar to the mechanism described for protein kinase A, in which phosphorylation of the equivalent threonine positions the activation loop to allow better substrate access in the groove between the two lobes of the enzyme structure (19).

Pak Activation by GTPases/Lipids-- How does GTPase binding interfere with the intramolecular interaction within the Pak molecule? In our studies, we could localize the interacting and autoinhibitory domain in the amino terminus to amino acids 67-150 of human Pak1. This region contains also contains the p21-binding domain. The minimal requirement for GTPase binding that has been defined by Burbelo et al. (14) spans amino acids 75-89 of human Pak1. However, it has been shown that amino acids both amino- and carboxyl-terminal of the minimal site enhance the binding affinity to the GTPases (9). We established, using previously characterized amino acid substitutions in Pak1, that both domains overlap but are at least partially separable. Mutating histidine 83 to leucine resulted in a drastic loss of Cdc42-binding, whereas this mutant still efficiently inhibited Pak1 kinase activity. On the other hand, mutation of leucine 107 to phenylalanine, previously demonstrated to activate full-length Pak1 kinase, maintained effective binding to GTPases but prevented interaction with the kinase domain. Histidine 86 is a key residue for both GTPase binding and autoinhibition. While this mutation seems not to affect the interaction with the kinase domain, as indicated by our GST pull-down assay, histidine 86 does make a functionally important contact required for inhibition of the Pak kinase core. Histidine 86 thus defines an overlapping site encompassing the end of the GTPase binding domain and the start of the autoinhibitory domain. The close proximity between the GTPase-binding and autoinhibitory domains suggests a simple model for the opening of the Pak structure. Binding of the GTPase to the PBD/ID interferes with functionally important regions of the autoinhibitory module and consequently separates the intramolecular interaction.

We propose that stimulating lipids, like sphingosine, induce Pak kinase activation in a similar fashion as small GTPases. Indeed, previous observations (11) suggested that the lipid interaction domain is also located (at least in part) within the characterized PBD/ID region. Sphingosine action on hPak1 leads to phosphorylation of threonine 423, as does activated GTPase. We therefore believe that sphingosine interferes with the autoinhibitory module leading to opening of the Pak structure. We have been unable to show that sphingosine disrupts the interaction in our established pull-down assay, however, probably due to the need to use non ionic detergents to prevent unspecific binding of the amino-terminal fragments (hpak1-(1-234), hpak1-(67-150)) to glutathione-agarose. The presence of the detergents destroys lipid vesicle formation necessary for sphingosine to act properly.

Zhao et al. (9) have recently described an autoinhibitory region by in vitro kinase assays in rat alpha Pak, which is the rat homologue of human Pak1. Rat and human Pak1 are more than 98% identical and differ only at seven amino acid positions located in the NH2-terminal regulatory region. Consistent with the autoinhibitory function described, we characterized the inhibitory domain in biochemical interaction assays using recombinant proteins. Zhao et al. (9) identified an autoinhibitory region from amino acid 83 to 149 that is contained within our minimal inhibitory region spanning amino acids 67-150 (the numbering of amino acids between rat alpha  Pak and human Pak1 is identical up to amino acid 178, where human Pak1 contains an additional aspartic acid residue). Using mutagenesis, they identified additional amino acids (conserved in hPak1) essential for the inhibitory function. These amino acids are located within the COOH-terminal portion of the PBD/ID region (glutamic acid 116/glutamine 117 and aspartic acid 126). As we demonstrated for leucine 107, these mutations do not disrupt GTPase binding but abolish the inhibitory function, supporting the idea that both functions have different determinants within this region. A more indirect approach using the yeast two-hybrid system was used to demonstrate that the equivalent regulatory and kinase domains of the yeast S. pombe Pak1 interact in a Cdc42-sensitive fashion (10).

Most of the Pak-homologous kinases, in addition to the minimal GTPase binding domain, exhibit sequence homologies in the immediate carboxyl-terminal region where determinants for the autoinhibitory module are located, suggesting that the described mechanism of kinase inhibition/activation is conserved within the Pak kinase family. Interestingly, a recently isolated and characterized Pak isoform, Pak4, shows constitutive kinase activity, independent of the binding of GTPases. Pak4 contains a p21-binding domain, but does not share homology in the carboxyl-terminal portion of this region where determinants for the inhibitory domain are located (21).

Threonine 423 in the Activation Loop as a Key Regulatory Site-- Phosphorylation of threonine 423 seems to be a key event for full activation of Pak1 and maintaining the kinase in a catalytically competent state. Studies on Pak65 (4) suggested that autophosphorylation of the kinase domain results from inter- and not intramolecular phosphorylation events. For protein kinase A, it has been proposed that phosphorylation within the activation loop might occur through an intermolecular mechanism (19). Due to its position and proximity to the catalytic center, we consider it unlikely that threonine 423 can be phosphorylated in cis (Fig. 9B). Although we cannot fully exclude this possibility, we were able to show that threonine 423 is accessible for intermolecular phosphorylation.

Our intermolecular phosphorylation studies showed that threonine 423 is not accessible in the closed Pak structure (Fig. 9B). Threonine 423 was only phosphorylated in Pak1-(K299A) when activated GTPase or sphingosine were added, indicating that opening of the Pak structure is required to make threonine 423 accessible for intermolecular phosphorylation. Whether the autoinhibitory module physically masks threonine 423 from phosphorylation or whether it induces a structural change in the kinase domain as depicted in the model in Fig. 9B is not clear.

Intermolecular phosphorylation only occurs if the Pak molecules are bound to activators. We envision this as a mechanism to spatially regulate Pak activation inside the cell, for example to areas where GTPases are localized. Inactive Pak molecules not interacting with GTPases/lipids cannot be activated by intermolecular phosphorylation, thereby preventing an undesirable chain reaction of Pak activation.

    ACKNOWLEDGEMENTS

We thank Erica M. Dutil and Alexandra C. Newton for their excellent phosphospecific anti-PKCbeta II antiserum and Melanie H. Cobb for providing the pGEX-KG/rpak1 construct. We thank Toni Lestelle for expert secretarial assistance.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants GM 39434 and AG15430 (to G. M. B.). This is publication 12434-IMM from the Scripps Research Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by an EMBO postdoctoral fellowship.

§ Recipient of a postdoctoral fellowship from the National Arthritis Foundation.

To whom correspondence should be addressed: Immunobiology-IMM14, Scripps Research Inst., 10550 N. Torrey Pines Rd., La Jolla, CA 92037.

    ABBREVIATIONS

The abbreviations used are: Pak, p21-activated kinase; GST, glutathione S-transferase; ID, inhibitory domain; MBP, myelin basic protein; PBD, p21-binding domain; PAGE, polyacrylamide gel eletrophoresis; DTT, dithiothreitol; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; PKC, protein kinase C; PCR, polymerase chain reaction; aa, amino acid(s).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Taylor, S. S., and Radzio-Andzelm, E. (1997) Curr. Opin. Chem. Biol. 1, 219-226[CrossRef][Medline] [Order article via Infotrieve]
2. Kemp, B. E., and Pearson, R. B. (1991) Biochim. Biophys. Acta 1094, 67-76[Medline] [Order article via Infotrieve]
3. Sells, M. A., and Chernoff, J. (1997) Trends Cell Biol. 7, 162-167
4. Benner, G. E., Dennis, P. B., and Masaracchia, R. A. (1995) J. Biol. Chem. 270, 21121-21128[Abstract/Free Full Text]
5. Yu, J. S., Chen, W. J., Ni, M. H., Chan, W. H., and Yang, S. D. (1998) Biochem. J. 334, 121-131
6. Lee, N., MacDonald, H., Reinhard, C., Halenbeck, R., Roulston, A., Shi, T., and Williams, L. T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13642-13647[Abstract/Free Full Text]
7. Rudel, T., and Bokoch, G. M. (1997) Science 276, 1571-1574[Abstract/Free Full Text]
8. Walter, B. N., Huang, Z., Jakobi, R., Tuazon, P. T., Alnemri, E. S., Litwack, G., and Traugh, J. A. (1998) J. Biol. Chem. 273, 28733-28739[Abstract/Free Full Text]
9. Zhao, Z. S., Manser, E., Chen, Z. Q., Chong, C., Leung, T., and Lim, L. (1998) Mol. Cell. Biol. 18, 2153-2163[Abstract/Free Full Text]
10. Tu, H., and Wigler, M. (1999) Mol. Cell. Biol. 19, 602-611[Abstract/Free Full Text]
11. Bokoch, G. M., Reilly, A. M., Daniels, R. H., King, C. C., Olivera, A., Spiegel, S., and Knaus, U. G. (1998) J. Biol. Chem. 273, 8137-8144[Abstract/Free Full Text]
12. Lian, J. P., Huang, R., Robinson, D., and Badwey, J. A. (1998) J. Immunol. 161, 4375-4381[Abstract/Free Full Text]
13. Sells, M. A., Knaus, U. G., Bagrodia, S., Ambrose, D. M., Bokoch, G. M., and Chernoff, J. (1997) Curr. Biol. 7, 202-210
14. Burbelo, P. D., Dreschsel, D., and Hall, A. (1995) J. Biol. Chem. 270, 29071-29074[Abstract/Free Full Text]
15. Daniels, R. H., Zenke, F. T., and Bokoch, G. M. (1999) J. Biol. Chem. 274, 6047-6050[Abstract/Free Full Text]
16. Brown, J. L., Stowers, L., Baer, M., Trejo, J., Coughlin, S., and Chant, J. (1996) Curr. Biol. 6, 598-605[CrossRef][Medline] [Order article via Infotrieve]
17. Martin, G. A., Bollag, G., McCormick, F., and Abo, A. (1995) EMBO J. 14, 1970-1978[Medline] [Order article via Infotrieve]
18. Manser, E., Huang, H. Y., Loo, T. H., Chen, X. Q., Dong, J. M., Leung, T., and Lim, L. (1997) Mol. Cell. Biol. 17, 1129-1143[Abstract]
19. Steinberg, R. A., Cauthron, R. D., Symcox, M. M., and Shuntoh, H. (1993) Mol. Cell. Biol. 13, 2332-2341[Abstract/Free Full Text]
20. Knaus, U. G., Wang, Y., Reilly, A. M., Warnock, D., and Jackson, J. H. (1998) J. Biol. Chem. 273, 21512-21518[Abstract/Free Full Text]
21. Abo, A., Qu, J., Cammarano, M. S., Dan, C., Fritsch, A., Baud, V., Belisle, B., and Minden, A. (1998) EMBO J. 17, 6527-6540[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Hum Mol GenetHome page
S. Nola, M. Sebbagh, S. Marchetto, N. Osmani, C. Nourry, S. Audebert, C. Navarro, R. Rachel, M. Montcouquiol, N. Sans, et al.
Scrib regulates PAK activity during the cell migration process
Hum. Mol. Genet., November 15, 2008; 17(22): 3552 - 3565.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. D. Smith, Z. M. Jaffer, J. Chernoff, and A. J. Ridley
PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics
J. Cell Sci., November 15, 2008; 121(22): 3729 - 3736.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Ambrogio, C. Voena, A. D. Manazza, C. Martinengo, C. Costa, T. Kirchhausen, E. Hirsch, G. Inghirami, and R. Chiarle
The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation
Cancer Res., November 1, 2008; 68(21): 8899 - 8907.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Maceyka, S. E. Alvarez, S. Milstien, and S. Spiegel
Filamin A Links Sphingosine Kinase 1 and Sphingosine-1-Phosphate Receptor 1 at Lamellipodia To Orchestrate Cell Migration
Mol. Cell. Biol., September 15, 2008; 28(18): 5687 - 5697.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
L. Li, Y. H. El-Hayek, B. Liu, Y. Chen, E. Gomez, X. Wu, K. Ning, L. Li, N. Chang, L. Zhang, et al.
Direct-Current Electrical Field Guides Neuronal Stem/Progenitor Cell Migration
Stem Cells, August 1, 2008; 26(8): 2193 - 2200.
[Abstract] [Full Text] [PDF]